| Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the … BJ Edwards, AD Bunta, J Lane, C Odvina, DS Rao, DW Raisch, ... The Journal of bone and joint surgery. American volume 95 (4), 297, 2013 | 139 | 2013 |
| Life-threatening dermatologic adverse events in oncology AC Rosen, Y Balagula, DW Raisch, V Garg, B Nardone, N Larsen, ... Anti-cancer drugs 25 (2), 225, 2014 | 71 | 2014 |
| Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's Adverse Event Reporting System and review of case reports in the … DW Raisch, V Garg, R Arabyat, X Shen, BJ Edwards, FH Miller, JM McKoy, ... Expert opinion on drug safety 13 (1), 15-23, 2014 | 40 | 2014 |
| Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting J Schmier, K Ogden, N Nickman, MT Halpern, M Cifaldi, A Ganguli, Y Bao, ... Clinical therapeutics 39 (8), 1600-1617, 2017 | 34 | 2017 |
| Impact of participation in the adalimumab (Humira) patient support program on rheumatoid arthritis treatment course: results from the PASSION study F Van den Bosch, AJK Ostor, S Wassenberg, N Chen, C Wang, V Garg, ... Rheumatology and therapy 4, 85-96, 2017 | 33 | 2017 |
| Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication DW Raisch, W Campbell, V Garg, ZP Qureshi, PB Bookstaver, LAB Norris, ... Expert opinion on drug safety 10 (4), 521-528, 2011 | 33 | 2011 |
| Noninsulin pharmacological management of type 1 diabetes mellitus V Garg Indian journal of endocrinology and metabolism 15 (Suppl1), S5, 2011 | 30 | 2011 |
| Risk of developing additional immune-mediated manifestations: a retrospective matched cohort study D Aletaha, AJ Epstein, M Skup, P Zueger, V Garg, R Panaccione Advances in therapy 36, 1672-1683, 2019 | 29 | 2019 |
| Economic impact of non-medical switching from originator biologics to biosimilars: a systematic literature review Y Liu, M Yang, V Garg, EQ Wu, J Wang, M Skup Advances in Therapy 36, 1851-1877, 2019 | 28* | 2019 |
| Use of number needed to treat in cost-effectiveness analyses V Garg, X Shen, Y Cheng, JJ Nawarskas, DW Raisch Annals of Pharmacotherapy 47 (3), 380-387, 2013 | 25 | 2013 |
| Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States ZP Qureshi, LA Norris, O Sartor, JM McKoy, J Armstrong, DW Raisch, ... Journal of Oncology Practice 8 (2), 84-90, 2012 | 22 | 2012 |
| Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis V Garg, DW Raisch, JP Selig, TA Thompson Prostate Cancer and Prostatic Diseases 16 (2), 193-203, 2013 | 20 | 2013 |
| Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis E Murray, A Ellis, Y Butylkova, M Skup, J Kalabic, V Garg Journal of comparative effectiveness research 7 (10), 959-974, 2018 | 16 | 2018 |
| Real-world effectiveness of biologic disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis after etanercept discontinuation in the United Kingdom … N Li, KA Betts, AJ Messali, M Skup, V Garg Clinical Therapeutics 39 (8), 1618-1627, 2017 | 16 | 2017 |
| A literature review of cost–effectiveness analyses of prostate-specific antigen test in prostate cancer screening V Garg, NY Gu, ME Borrego, DW Raisch Expert review of pharmacoeconomics & outcomes research 13 (3), 327-342, 2013 | 16 | 2013 |
| Long-term effectiveness of adalimumab in patients with rheumatoid arthritis: an observational analysis from the Corrona rheumatoid arthritis registry DA Pappas, JM Kremer, J Griffith, G Reed, B Salim, C Karki, V Garg Rheumatology and therapy 4, 375-389, 2017 | 12 | 2017 |
| Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis … D Aletaha, SJ Snedecor, V Ektare, M Xue, Y Bao, V Garg ClinicoEconomics and Outcomes Research, 451-458, 2017 | 10 | 2017 |
| Similar improvements in patient-reported outcomes among rheumatoid arthritis patients treated with two different doses of methotrexate in combination with adalimumab: results … GS Kaeley, DK MacCarter, JR Goyal, S Liu, K Chen, J Griffith, H Kupper, ... Rheumatology and Therapy 5, 123-134, 2018 | 8 | 2018 |
| Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs V Garg, DW Raisch, JM McKoy, SM Trifilio, J Holbrook, BJ Edwards, ... Expert opinion on drug safety 12 (3), 299-307, 2013 | 8 | 2013 |
| A matching-adjusted indirect comparison of upadacitinib versus tofacitinib in adults with moderate-to-severe rheumatoid arthritis CJ Edwards, R Sawant, V Garg, EX Du, A Friedman, KA Betts Rheumatology and Therapy 8, 167-181, 2021 | 6 | 2021 |
